Grants Search Results

This grant helps provide necessary resources for the Late Effects/Survivorship Program at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

Juvenile myelomonocytic leukemia (JMML) is a rare but deadly form of childhood leukemia that is very difficult to diagnose. This grant helps provide necessary resources at this institution to establish a diagnostic center of excellence for pediatric myeloproliferative neoplasms, focusing on JMML.

This grant brings together SIOP's Working Group on Essential Medicines, a group of experts from around the globe, to develop a multi-faceted approach to increase the availability of essential medicines for young people with childhood cancer world-wide.

With acute lymphoblastic leukemia (ALL) patients facing a 20% chance of relapse and poor prognosis, as well as substantial short and long term side effects from conventional therapy, novel approaches using targeted therapy based on the intrinsic biology of the ALL blast are urgently needed. The SPORE in Childhood ALL is an ambitious multi-institutional grant that brings together a talented and productive group of basic, translational and clinical investigators who have a strong history of collaborative efforts.  There has never been a SPORE focused on childhood cancer in the history of the National Cancer Institute (NCI), and this grant funds the planning necessary to submit the SPORE for NCI approval.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

Based on progress to date, Dr. Cho, Miracles in Memory of Michael St. Baldrick's Scholar, was awarded a new grant in 2014 to fund an additional two years of this Scholar award. Medulloblastoma is the most common brain cancer in children. Currently, these children undergo surgery and aggressive radiation and chemotherapy, and still about 35% do not survive. Survivors are often left with permanent disabilities with learning, strength and coordination. There is a critical need for newer, more 'targeted' therapies that will not only increase survival of patients, but also prevent damage to the normal brain. The goal of Dr. Cho's research is to identify the molecular factors that medulloblastomas rely on for growth and survival, in order to develop new strategies to more effectively treat children diagnosed with this lethal disease. Awarded at Children's Hospital Boston, transferred to Stanford University, and transferred to Oregon Health & Science University.

This grant is named for the Miracles in Memory of Michael Fund created in memory of Michael Orbany and honors his tremendous strength to never ever give up.

Based on progress to date, Dr. Schultz was awarded a new grant in 2014 to fund an additional two years of this Scholar award. Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have recently been found to be associated with a lung cancer of early childhood called pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1 mutations are seen in the majority of children with PPB and also in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly curable when found in early stage; however, later forms of the disease are aggressive and often fatal. This project establishs the International Ovarian Stromal Tumor Registry to collect clinical and biologic data. Understanding these rare tumors will lead to increasing survival and reducing late effects. The Registry provides information to improve the direct care of children with these conditions and facilitate future research.  

Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), the most common class of soft tissue sarcoma, afflicts children and young adults. Unlike children with rhabdomyosarcoma, chemotherapy has failed to improve survival for NRSTS. Of the nearly 50% with intermediate or high-risk NRSTS, only 50% and 15%, respectively, are expected to survive. This consortium is taking advantage of new technology platforms to identify the so-called "actionable mutations" in NRSTS specimens. From this foundation, researchers are able to use molecular genetic data to guide treatment decisions for individual patients with NRSTS. Funds originally administered by the University of Chicago and transferred to the University of Texas Southwestern Medical Center at Dallas.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

Cancer is caused by alterations (mutations) in the genetic material of tumor cells. The identification of these mutations has allowed the development of treatments specifically targeted at the mutated genes, resulting in remarkable clinical advances for a few specific cancer types. This proposal uses state-of-the-art sequencing technologies to analyze hepatoblastoma, the most common liver cancer of children. The goal of this project is to dramatically shift current research and treatment paradigms by directing investigators to the most relevant genes causing hepatoblastoma, which are currently largely unknown.  

T-cell acute lymphoblastic leukemia is an aggressive cancer that requires highly intensive chemotherapy, and the prognosis of patients with relapsed and refractory T-ALL is very poor. The genetic lesions responsible for progression and relapse in this disease remain largely unknown. The goals of this project are to identify novel pathogenic genes and pathways in relapsed and refractory T-ALL, to assess their contribution to T-cell transformation and chemotherapy resistance. These results will be ultimately translated in new diagnostic tools to identify high-risk patients and in new molecular targeted drugs for the treatment of this disease.

Neuroblastoma is the second most common solid cancer in childhood. Half of patients are at an advanced stage at diagnosis, difficult to treat successfully even with aggressive therapy. Ferritin is the body's storage form of iron, and elevated levels have been linked to worse outcomes in patients with neuroblastoma, but this phenomenon is still poorly understood. This research is investigating how genetic mutations in HFE, the gene responsible for the iron overload disorder, promote the development and spread of neuroblastoma cells. By identifying which specific iron metabolism pathways are involved, we can come up with new therapeutic strategies that are more specific and less toxic.

Osteosarcomas are a devastating pediatric bone cancer for which survival rates have not improved over 30 years. Current treatments remain aggressive and are prone to relapse. A new gene has been identified called Sox2, upon which osteosarcoma cells depend for survival. This project will evaluate whether strategies for blocking Sox2 function in tumors can eradicate the tumor and all residual cells to prevent relapse of the disease. These studies provide a novel basis for the targeted treatment of this childhood cancer and lead to a better understanding of the cancer stem cells that give rise to tumors.